Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide + trifluridine/tipiracil vs trifluridine/tipiracil in third-line or later advanced colorectal cancer
ChiCTR2100051262Phase 2Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in colorectal adenocarcinoma comparing Thalidomide + trifluridine/tipiracil with Trifluridine/tipiracil alone (2 arms). Primary endpoints: Toxic and side effects, Overall survival and 3 more. Started Oct 2021; status: recruiting.
02
Drugs
thalidomidetrifluridine + tipiracil
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2100051262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051262.